Navigation Links
Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
Date:9/1/2011

financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “project,” “intend,” “plan,” “will,” “target,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) any changes in the patterns of medical reimbursement that may result from national healthcare reform; (4) our ability to successfully operate our business, including successfully converting our increasing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and selling these products and services under the MedGraphics and New Leaf brand names into existing and new markets; (5) our ability to complete our  software development initiatives and migrate our MedGraphics and New Leaf platforms to a next generation technology; (6) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (7) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (8) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (9) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory d
'/>"/>
SOURCE Angeion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Calif. , July 27, 2015 Allergan ... (NASDAQ: KYTH ) today announced that the U.S. ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... acquisition of KYTHERA.  Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO ... of Allergan and KYTHERA filed a Pre-Merger Notification and ...
(Date:7/27/2015)... 2015   Mallinckrodt plc (NYSE: ... today that it has entered into a definitive ... contrast media and delivery systems (CMDS) business to ... at approximately $270 million.   Mallinckrodt,s ... with the company,s stated plan to strategically streamline ...
(Date:7/27/2015)... -- EnzymeBioSystems (OTC BB: ENZB - News) announces that a ... the Company,s lead pharmaceutical product. EnzymeBioSystems plans to seek ... prevention of breast cancer. "We are pleased ... has been completed," stated Gary Rojewski , CEO ... will allow us to move forward in beginning to ...
Breaking Medicine Technology:Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 2Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 3Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 4Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 5Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 6Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 7Amooranin Preclinical Sample Batch Completed 2
... Determine How Chest X-Ray CAD Could ... High-Tech Tool for Early Detection, Increased Patient ... and Riverain Medical,today announced the establishment of the ... chest X-ray CAD (computer-aided detection) can improve,practical early ...
... 26 CuraGen Corporation,(Nasdaq: CRGN ), a ... (Copenhagen Stock Exchange: TOPO) announced,today that updated preliminary ... belinostat for T-cell lymphomas, and new preclinical data,evaluating ... presented,at the 2007 American Society of Hematology (ASH) ...
Cached Medicine Technology:Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 2Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 3Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 4Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 5Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 6Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 7CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5
(Date:7/27/2015)... ... 27, 2015 , ... BESLER Consulting today announced the publication ... for Medicare and Medicaid Services (CMS) provides each hospital affected by the HRRP ... as the QualityNet Hospital-Specific Report (HSR), this report contains a variety of insights ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Gary ... Jersey. Dr. Breslow is Founder and Medical Director of The Breslow Center in ... the face, breast, and body in Northern New Jersey. The Breslow Center also ...
(Date:7/27/2015)... ... 27, 2015 , ... For a limited time, Huntington Beach dentist , ... is a great time to change up a look or to simply brighten a ... affect your self-esteem. Over time, the enamel coating can become worn and can expose ...
(Date:7/27/2015)... ... 2015 , ... According to an article published by the Times Free ... Tennessee stemming from intravenous drug use. Intravenous drug use causes more overdoses and is ... diseases including Hepatitis B and C and HIV. Drug treatment facilities in Tennessee have ...
(Date:7/27/2015)... ... July 27, 2015 , ... Hexagon ... new way to understand and share your geospatial experience. These new light-weight applications ... to solve distinct business problems. , “Our world is more dynamic than it ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Doc, Dr. Gary Breslow, has launched Zwivel; a New Online Cosmetic Consultation Service for Doctors and Patients 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 3Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 2Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 3
... disease, experts say, , , THURSDAY, May 21 (HealthDay ... levels also reduce their risk of heart attack ... have been several conflicting reports about the value ... patients in preventing heart attack and heart disease. ...
... Bayer HealthCare Pharmaceuticals, Inc. today announced that ... 73-4506 (DAST-Inhibitor) will be presented at the 45th Annual ... in Orlando, Florida, May 29 - June 2. ... the oral multi-kinase inhibitor BAY 73-4506 is one of ...
... Omnicare, Inc., which calls itself "the nation,s leading ... to settle Medicaid fraud charges by the State ... had committed Medicaid fraud by illegally switching the ... other facilities. Omnicare,s conduct had originally been ...
... New Method for Optimizing Cardiac Resynchronization Therapy During Exercise. The ... difference in treating CRT patients." Dr. Abraham Kocheril, Professor of ... Illinois at Chicago. , ... Minneapolis-St. ...
... A protein that plays a key role in tumor formation, ... that extends lifespan by dietary restriction. The finding, which appears ... PLoS Genetics , provides a new understanding of how ... scientists new targets for developing and testing drugs that could ...
... and lifestyle characteristics can be linked to different invasive ... presented in the open access journal Breast Cancer ... of the condition are associated with different kinds of ... Research, California, led a team of researchers who used ...
Cached Medicine News:Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 2Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 3Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 2Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 2Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 4Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 5Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 2Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 3Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 4Health News:Key protein may explain the anti-aging and anti-cancer benefits of dietary restriction 2
3.5v Coaxial Ophthalmoscope Set with Convertible Handle and Hard Case. Our 3.5v Coaxial Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
High-quality eyecare from the preferred name in diagnostic instruments....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: